Investors Buy High Volume of Call Options on uniQure (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) was the target of unusually large options trading activity on Wednesday. Stock investors bought 11,127 call options on the stock. This represents an increase of 28% compared to the typical volume of 8,707 call options.

Insiders Place Their Bets

In related news, insider Walid Abi-Saab sold 45,000 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider directly owned 169,669 shares in the company, valued at $4,251,905.14. This trade represents a 20.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $431,228.16. Following the completion of the transaction, the insider owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 85,817 shares of company stock worth $2,232,383. Company insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently bought and sold shares of the company. Woodline Partners LP boosted its holdings in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the last quarter. Legal & General Group Plc bought a new stake in uniQure in the 2nd quarter worth approximately $497,000. Marshall Wace LLP grew its position in uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after purchasing an additional 163,749 shares during the period. California State Teachers Retirement System bought a new stake in uniQure in the 2nd quarter worth approximately $540,000. Finally, Ameriprise Financial Inc. raised its stake in uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after buying an additional 212,218 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure Stock Up 78.8%

NASDAQ:QURE traded up $21.26 on Wednesday, reaching $48.25. 9,952,452 shares of the stock traded hands, compared to its average volume of 2,627,439. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -13.98 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The company’s fifty day simple moving average is $22.93 and its 200 day simple moving average is $21.75.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities analysts predict that uniQure will post -3.64 EPS for the current fiscal year.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure announced plans to submit a BLA for AMT-130, saying the FDA agreed the company’s three-year data could serve as the primary basis for an accelerated approval filing. Article Title
• Positive Sentiment: Public reports indicate the FDA’s recent dialogue was more favorable than earlier guidance, which had suggested uniQure might need a larger randomized trial; that shift materially improves the near-term regulatory path. Article Title
• Neutral Sentiment: Trading volume jumped and the stock attracted unusual call option activity, suggesting traders are positioning aggressively around the FDA news rather than on operating results alone.
• Neutral Sentiment: Recent insider and institutional trading data show mixed longer-term sentiment, but these flows are secondary to today’s regulatory catalyst.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. TD Cowen reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Chardan Capital increased their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. Finally, Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Eleven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.